(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;hydrochloride

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;hydrochloride
• 化学式: C27H31ClF6N2O2
• 分子量: 565.0
• InChiKey: VIGHLYLHOIRTLS-LDYXWBQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.0
• 重原子数：
  38
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  58.2
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Composition and method for therapeutic agent delivery during pregnancy
  申请人：University of Mississippi Medical Center

  公开号：US10081667B2

  公开（公告）日：2018-09-25

  A composition including an elastin-like polypeptide (ELP) coupled to a therapeutic agent is provided. The ELP comprises at least about 5 repeats of the amino acid sequence VPGXG. Further provided is a method of using the composition for therapeutic agent delivery during pregnancy to reduce the amount of the therapeutic agent crossing a placenta in a pregnant subject. The method includes administering to the pregnant subject an effective amount of the composition comprising the ELP coupled to the therapeutic agent.

  提供了一种组合物，其中包括一种与治疗剂结合的弹性蛋白样多肽（ELP）。ELP 包含至少约 5 个重复的氨基酸序列 VPGXG。还提供了一种在怀孕期间使用该组合物输送治疗剂的方法，以减少治疗剂通过怀孕对象胎盘的量。该方法包括向怀孕对象施用有效量的组合物，该组合物包含与治疗剂偶联的ELP。
• PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF
  申请人：Aciex Therapeutics, Inc.

  公开号：EP2941437A1

  公开（公告）日：2015-11-11
• ELASTIN-LIKE POLYPEPTIDE COUPLED TO THERAPEUTIC AGENT FOR DELIVERY DURING PREGNANCY
  申请人：University of Mississippi Medical Center

  公开号：EP3052125B1

  公开（公告）日：2020-09-30
• EP3785725A1
  申请人：——

  公开号：EP3785725A1

  公开（公告）日：2021-03-03
• Composition and Method for Therapeutic Agent Delivery During Pregnancy
  申请人：UNIVERSITY OF MISSISSIPPI MEDICAL CENTER

  公开号：US20160297868A1

  公开（公告）日：2016-10-13

  A composition including an elastin-like polypeptide (ELP) coupled to a therapeutic agent is provided. The ELP comprises at least about 5 repeats of the amino acid sequence VPGXG. Further provided is a method of using the composition for therapeutic agent delivery during pregnancy to reduce the amount of the therapeutic agent crossing a placenta in a pregnant subject. The method includes administering to the pregnant subject an effective amount of the composition comprising the ELP coupled to the therapeutic agent.